New Treatment for Primary Generalized Tonic-Clonic Seizures PGTCS

Lead researcher, Dr. David Vossler, MD, FAAN FACNS FAES, Department of Neurology, University of Washington, discusses the recent U.S. FDA approval of UCB’s VIMPAT® (lacosamide) CV as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients four years of age and older and VIMPAT injection for intravenous use in children four years of age and older.

David Vossler, MD, holds his Doctor of Medicine degree, cum laude from Jefferson Medical College of Thomas Jefferson University, and Bachelor or Arts, magna cum laude from University of Rochester in Rochester, New York. He completed his Neurology Residency at Boston University in 1987. He completed an additional Fellowship in Clinical Neuro-physiology in 1989 at University of Washington. Dr. Vossler is the Medical Director of The Neuroscience Institute and a national authority on epilepsy and clinical neurophysiology. He has authored over 50 scientific articles and has served on journal editorial boards and boards of national neurology organizations. Dr. Vossler treats people with seizure disorders using standard medical and surgical techniques, and conducts ongoing research. He has received numerous professional honors. He was also named “Best Doctor” in the category of neurology by Washington State Travel and Life magazine. In his personal time, he is an active volunteer for the Boy Scouts of America, conducts epilepsy research and, with his wife, raises four children. He enjoys skiing, camping, hiking, motorcycle touring and bicycling.